CETUXIMAB

作品数：108被引量：265H指数：9
导出分析报告
相关领域：医药卫生更多>>
相关作者：夏良平郭桂芳周菲菲丘惠娟张蓓更多>>
相关机构：中山大学军事医学科学院四川省肿瘤医院浙江理工大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金“重大新药创制”科技重大专项广东省自然科学基金上海市自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Penile metastasis from colon cancer with BRAF_(V600E)mutation treated with BRAF/MEK-targeted therapy plus cetuximab:A case report
《World Journal of Gastrointestinal Oncology》2025年第3期402-409,共8页Jun-Chen Wu Hua-Xi Cheng Qiu-Sheng Lan He-Yang Xu Yu-Jie Zeng Wei Lai Zhong-Hua Chu 
National Natural Science Foundation of China,No.81871981;Natural Science Foundation of Guangdong Province,No.2022A1515012348 and No.2023A1515010457.
BACKGROUND The incidence of colon cancer has been progressively increasing over time,whereas penile metastasis of colon cancer has remained exceedingly uncommon.Since the prognosis for colon cancer with BRAF_(V600E)mu...
关键词：Colon cancer Penile metastasis BRAF_(V600E)mutation Targeted therapy Case report 
美国FDA批准Krazati(adagrasib/阿达格拉西布)与西妥昔单抗(cetuximab)联用治疗KRAS G12C突变结直肠癌
《广东药科大学学报》2024年第5期131-131,共1页夏训明(编译) 
美国FDA于2024年6月21日通过加速审批程序(accelerated approval pathway,一种临时性的新药审批机制)批准Krazati(adagrasib/阿达格拉西布,研发代号MRTX849;CAS登记号:2326521-71-3;分子式:C32H35ClFN7O2)与西妥昔单抗(cetuximab,CAS登...
关键词：西妥昔单抗 新药审批 转移性结直肠癌 伊立替康 联合用药 登记号 格拉西 
Successful cetuximab rechallenge in metastatic colorectal cancer:A case report
《World Journal of Clinical Oncology》2024年第9期1232-1238,共7页Alexandra Guedes Sandra Silva Sandra Custódio Andreia Capela 
BACKGROUND Metastatic colorectal cancer(mCRC)treatment has been evolving and increasingly driven by tumor biology and gene expression analysis.Rechallenge with epidermal growth factor receptor(EGFR)inhibitors(anti-EGF...
关键词：Metastatic colorectal cancer RAS mutation RAS wild type Anti-epidermal growth factor receptor CETUXIMAB RECHALLENGE Case report 
BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib,binimetinib,and cetuximab:A case report
《World Journal of Gastrointestinal Oncology》2024年第7期3357-3363,共7页Makiko Sasaki Takaya Shimura Hirotada Nishie Keita Kuroyanagi Takuya Kanno Shigeki Fukusada Naomi Sugimura Yusuke Mizuno Takayuki Nukui Konomu Uno Yuki Kojima Ruriko Nishigaki Mamoru Tanaka Keiji Ozeki Eiji Kubota Hiromi Kataoka 
BACKGROUND BRAF mutation has been recognized as a negative prognostic marker for metastatic colorectal cancer(mCRC),but these data are from common BRAF V600E-mutated mCRC.Combination therapy of BRAF inhibitor and anti...
关键词：BRAF K601E mutation Metastatic colorectal cancer Encorafenib Binimetinib CETUXIMAB Case report 
Combined treatment with cetuximab and STA9090 has synergistic anticancer effects on human non-small cell lung cancer
《Acta Biochimica et Biophysica Sinica》2024年第7期1022-1033,共12页Wanjun Lu Lixia Liu Xiang Kang Kangkang Ren Ye Huang Minzhang Cheng Xiaolei Li Fei Xu Xinping Xu 
supported by the grants from the National Natural Science Foundation of Jiangxi Province,China(Nos.20202ACBL206024 and 20212BAB206034);the Innovative and Entrepreneurial Youth Talents Project of Jiangxi(No.JXSQ2018106040);the Li Ka Shing Foundation LKSF(No.1210669001).
Cetuximab(CET),a human murine chimeric IgG monoclonal antibody and an inhibitor of epidermal growth factor receptor(EGFR),has been shown to be effective in treating various types of cancer.However,its use is hindered ...
关键词：CETUXIMAB STA9090 synergistic effect receptor tyrosine kinase non-small cell lung cancer 
Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care
《World Journal of Clinical Cases》2024年第18期3360-3367,共8页Hui Ying Ren-Jun Huang Xiao-Min Jing Yan Li Qun-Qiu Tong 
BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for imp...
关键词：CETUXIMAB FOLFOX4 regimen Evidence-based care Advanced gastric carcinoma Efficacy and safety 
Cetuximab combined with chemotherapy for simultaneous esophageal squamous cell carcinoma and colon adenocarcinoma:A case report
《World Journal of Clinical Cases》2024年第15期2649-2654,共6页Xin-Xin Luo Yu-Xuan Du Qi-Qing Zhang Lin Zhang Shu-Ying Zeng Zhi-Hong Yu Peng Shen Zheng-Quan Feng 
BACKGROUND Multiple primary carcinomas(MPCs)are defined as two or more independent primary cancers that occur simultaneously or sequentially in the same individual.Synchronous MPCs are rarer than solitary cancers or m...
关键词：Synchronous multiple primary carcinoma Esophageal squamous cell carcinoma Colon adenocarcinoma CETUXIMAB CHEMOTHERAPY Case report 
Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity
《Cancer Drug Resistance》2023年第4期709-728,共20页Hannah Zaryouh Ines De Pauw Hasan Baysal Joran Melis Valentin Van den Bossche Christophe Hermans Ho Wa Lau Hide Lambrechts Celine Merlin Cyril Corbet Marc Peeters Jan Baptist Vermorken Jorrit De Waele Filip Lardon An Wouters 
funded by“Kom op tegen Kanker”(Stand up to Cancer),the Flemish Cancer Society(grant number:34986).
Aim:Acquired resistance to the targeted agent cetuximab poses a significant challenge in finding effective anti-cancer treatments for head and neck squamous cell carcinoma(HNSCC).To accurately study novel combination ...
关键词：HNSCC cetuximab resistance xenograft mouse model immunodeficient mice 
Comprehensive next-generation sequencing reveals double primary colorectal carcinoma missed by diagnostic imaging: A case report
《World Journal of Gastrointestinal Oncology》2023年第10期1823-1828,共6页Yan-Jun Qu Qian-Shi Zhang Bo Wang Feng Zhang Evenki Pan Chun-Yan Zhao Si-Ye Liu Li-Ping Fang 
BACKGROUND Multiple primary colorectal carcinoma(MPCC)is a rare clinical disease,which is challenging to differentiate from metastatic disease using histopathological methods.Next-generation sequencing(NGS)has been em...
关键词：Multiple primary colorectal carcinoma Next-generation sequencing CETUXIMAB RET fusion Case report 
Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer被引量：1
《Acta Biochimica et Biophysica Sinica》2023年第9期1467-1478,共12页Yitao Yuan Xun Sun Mengling Liu Suyao Li Yu Dong Keshu Hu Jiayu Zhang Bei Xu Sining Ma Hesheng Jiang Pengcong Hou Yufu Lin Lu Gan Tianshu Liu 
supported by the grants from the National Natural Science Foundation of China(Nos.81802370 and 8217111492);the Special Clinical Research Program of Shanghai Municipal Health Commission Health Industry(No.202040222);the Xiamen Natural Science Foundation Project(No.3502Z20227111);the Shanghai Natural Science Foundation(No.23ZR1421300).
The emergence of anti-EGFR therapy has revolutionized the treatment of colorectal cancer(CRC).However,not all patients respond consistently well.Therefore,it is imperative to conduct further research to identify the m...
关键词：colorectal cancer cetuximab resistance ACAA2 Kras mutation 
全选清除导出
共11页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部